

**Supplementary Table 1.** NMO-IgG status, clinical features, and CSF findings in NMOsd patients

NMOsd	NMO-IgG serum/CSF	Clinical characteristics	CSF features					
			Protein, g/L	Glucose, mmol/L	Cells, n/mL	IgG index	Q <sub>Alb</sub> , (UL)	OCB
1	+/+	rLETM+rON	0.44	4.3	6	1.03	4.24 (6.73)	Negative
2	+/+	rLETM	0.32	3.2	3	0.51	5.77 (7.53)	Negative
3	-/NP	Simultaneous ON+LETM	0.62	4	12	0.58	6.45 (9)	Negative

LETM, longitudinal extensive transverse myelopathy; NMO, neuromyelitis optica spectrum; NP, not performed; OCB, oligoclonal bands; ON, optic neuritis; Q<sub>Alb</sub>, albumin ratio; rLETM, recurrent LETM; rON, recurrent optic neuritis; UL; upper limit

**Supplementary Table 2.** Treatment given by etiology

GROUP (n)	MTP	PLEX	Iv. IgG	Cyclophosphamide	Rituximab
Idiopathic (22)	18	1			
MS (18)	15	1			
PIM (11)	11		1		
SD (9)	9			3 **	
SCI (3)	3				
NMOsd (3)	3	2			2 *
ADEM (2)	2				
Dural fistula (2)	2				
Tumor related (2)	1				

ADEM, acute demyelinating encephalomyelitis; Iv IgG, intravenous immunoglobulins; MS, multiple sclerosis; NMOsd, neuromyelitis optica spectrum disorders; PIM, parainfectious myelitis; SD, systemic disease; SCI, spinal cord infarct

\*The two seropositive NMO patients.

\*\* All cases, systemic lupus erythematosus